In the Angiotensin-Converting Enzyme Inhibitors and Kidney Protection (AIPRI) trial comparing benazepril to placebo in patients with CKD, mostly without diabetes, a DBP reduction of 3.5 to 5.0 mmHg was noted in the benazepril group. Here, ACE is linked to chronic kidney disease.